A 48-year-old woman with newly diagnosed HER2-positive, hormone receptor-negative invasive ductal carcinoma of the breast is being evaluated for adjuvant therapy. What is the drug of choice for HER2-directed therapy in this patient?

Explanation

## HER2-Directed Therapy in HER2+ Breast Cancer ### HER2 Pathway Overview HER2 (human epidermal growth factor receptor 2) is a receptor tyrosine kinase that, when overexpressed or amplified, drives aggressive breast cancer growth. HER2+ tumors account for approximately 15–20% of breast cancers and require targeted therapy. ### Trastuzumab as First-Line HER2-Directed Agent **Key Point:** Trastuzumab (Herceptin), a monoclonal antibody against HER2, is the gold-standard first-line HER2-directed therapy for both early-stage and metastatic HER2+ breast cancer [cite:Harrison 21e Ch 397]. **High-Yield:** The landmark HERA trial demonstrated that one year of adjuvant trastuzumab significantly improves disease-free survival and overall survival in HER2+ early-stage breast cancer. Trastuzumab is now standard of care for all HER2+ patients. ### Mechanism of Action Trastuzumab is a humanized monoclonal antibody that: 1. Blocks HER2 signaling by preventing ligand-independent dimerization 2. Induces antibody-dependent cellular cytotoxicity (ADCC) via Fc receptor engagement 3. Inhibits HER2 shedding and downstream PI3K/Akt and MAPK/ERK pathways ### Comparison of HER2-Directed Agents | Agent | Class | Mechanism | Clinical Use | Timing | |-------|-------|-----------|--------------|--------| | **Trastuzumab** | Monoclonal antibody | HER2 blockade + ADCC | Early-stage & metastatic (1st-line) | All HER2+ patients | | Pertuzumab | Monoclonal antibody | HER2 dimerization inhibitor | Metastatic + neoadjuvant (dual blockade) | Added to trastuzumab in advanced disease | | T-DM1 | Antibody-drug conjugate | Trastuzumab + microtubule inhibitor | Metastatic after progression on trastuzumab | 2nd-line or later | | Lapatinib | Tyrosine kinase inhibitor | Dual HER2/EGFR inhibitor | Metastatic (alternative/salvage) | After trastuzumab resistance | ### Clinical Pearl **Dual HER2 Blockade:** In metastatic HER2+ disease, pertuzumab is added to trastuzumab to block different HER2 dimerization pathways, improving outcomes. However, in early-stage disease, trastuzumab monotherapy remains the standard unless there are high-risk features. ### Adverse Effects to Monitor - **Cardiotoxicity:** Trastuzumab causes reversible left ventricular dysfunction in 5–7% of patients. Baseline and serial echocardiography or MUGA scans are mandatory. - **Infusion reactions:** Fever, chills, dyspnea (usually with first infusion). - **Hypersensitivity:** Rare but serious. **Tip:** Always assess LVEF before starting trastuzumab. Concurrent anthracycline use increases cardiotoxicity risk; sequential rather than concurrent administration is preferred when possible.